Disease-Modifying Drugs for Rheumatoid Arthritis. When, How and Which One to Use
Abstract
Rheumatoid arthritis is the most common rheumatological disease worldwide, with many articular and extra-articular complications associated with comorbidities and mortality. Cardiac and pulmonary complications contribute the most towards morbidity, mortality and pose great difficulty in RA management. Recently there have been many updates in the pharmacological options available for rheumatoid arthritis, including biological and targeted biological disease-modifying drugs. This review article focuses on the pros and cons of the main therapeutic options currently used to manage rheumatoid arthritis according to the updated guidelines by EULAR. The report also encompasses a summary of the recent guidelines by EULAR.Keywords:
Rheumatoid arthritis, conventional Disease Modifying Anti Rheumatoid Drugs, Biological DMARD, Targeted DMARDsPublished
2021/09/20
Issue
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com